PAH News

October 14, 2020October 14, 2020

FDA Approves Clinical Trial of TIVUS System in PAH

News, PAH News

The U.S. Food and Drug Administration (FDA) has granted SoniVie permission to begin a pivotal clinical trial of its Therapeutic Intra-Vascular Ultrasound (TIVUS) System in people with pulmonary arterial hypertension ... Read more

October 12, 2020October 12, 2020

Newly Identified DNA Variants Affect BMPR2 Gene Activity in Familial PAH

News, PAH News

New variants in the DNA region that promote the activity of the BMPR2 gene — associated with familial pulmonary arterial hypertension (PAH) — lower the gene’s activity and may ... Read more

October 2, 2020October 2, 2020

FDA Asked to Approve Intravenous Uptravi as Option When Tablets Won’t Do

News, PAH News

Janssen Pharmaceutical has asked the U.S. Food and Drug Administration (FDA) to approve the use of intravenous Uptravi (selexipag) by pulmonary arterial hypertension (PAH) patients unable for a given time to use Uptravi ... Read more

September 30, 2020September 30, 2020

Letairis Shows Efficacy and Safety in Children With PAH in Phase 2b Trial

News, PAH News

Letairis (ambrisentan), an approved therapy for pulmonary arterial hypertension (PAH) in adults, appears to also be effective and safe in children ages 8 and older, a study based on clinical trial ... Read more

September 21, 2020September 21, 2020

Moderna, Chiesi Will Collaborate on New RNA-based Therapies for PAH

News, PAH News

Moderna has entered a collaboration agreement with Chiesi Farmaceutici to develop new messenger RNA-based therapies for pulmonary arterial hypertension (PAH). Messenger RNAs (mRNAs) are the molecules that cells use ... Read more

September 18, 2020September 18, 2020

Study Results Support Opsumit-Adcirca Combo for Newly Diagnosed PAH

News, PAH News

The combination of Opsumit (macitentan) and Adcirca (tadalafil) is a safe and effective initial treatment for pulmonary arterial hypertension (PAH), new clinical trial data show. The findings were published ... Read more

August 31, 2020August 31, 2020

U.S. Patent Approval Expected for LIQ861 Treprostinil Dry Powder

News, PAH News

Liquidia Technologies has received a notice of allowance from the U.S. Patent and Trademark Office, indicating that a patent application for LIQ861, the company’s investigational dry powder formulation of ... Read more

August 17, 2020August 17, 2020

Ambrisentan Ably Treats Chinese Patients with PAH-CTD, Study Reports

News, PAH News

Volibris (ambrisentan) given to treat adults in China with pulmonary arterial hypertension (PAH) caused by connective tissue disease led to significant improvements in exercise capacity without signs of clinical ... Read more

August 12, 2020August 14, 2020

Liquida’s LIQ861 Found to Improve Exercise Capacity, Quality of Life in PAH

News, PAH News

LIQ861, Liquidia Technologies’ proprietary inhaled dry powder formulation of the vasodilator treprostinil, improves exercise capacity and quality of life for people with pulmonary arterial hypertension (PAH), according to data ... Read more

August 10, 2020August 10, 2020

5-year Survival Rate Lower in Congenital Heart Disease Patients With PAH

News, PAH News

The five-year survival rate is markedly reduced among adults with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD), compared with other types of CHD, real-world data from ... Read more